Vizgen debuts accelerator lab in the U.S.

By The Science Advisory Board staff writers

January 6, 2021 -- Life sciences company Vizgen has established an accelerator lab in the U.S. to advance pharmaceutical research and development.

The pharma accelerator lab was launched to meet the high demand from pharmaceutical companies who continue to turn to single-cell and spatial transcriptomics technology to speed up drug development pipelines.

Additionally, Vizgen began an early release program so scientific investigators could gain access to its multiplexed error-robust fluorescence in situ hybridization (MERFISH) platform ahead of its commercial launch.

Global health R&D stalls as resources are redirected to COVID-19
The current coronavirus pandemic has set back progress in research and development (R&D) on neglected diseases and other long-standing global health challenges...
TreeFrog, Invetech partner on automated single-use stem cell encapsulation
TreeFrog Therapeutics and Invetech have entered a strategic partnership to develop a good manufacturing practices-compliant device for high-throughput...
Bio-Techne rebrands genome engineering as part of R&D Systems portfolio
Bio-Techne has rebranded its cell and gene engineering product offer as part of its R&D Systems biotechnology brand.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter